Copyright Reports & Markets. All rights reserved.

Drugs for Chronic Obstructive Pulmonary Disorder Market Research Report 2012-2024

Request for Sample of this report
Buy now

Table of Contents

    1 Market Overview

    • 1.1 Objectives of Research
      • 1.1.1 Definition
      • 1.1.2 Specifications
    • 1.2 Market Segment
      • 1.2.1 by Type
        • 1.2.1.1 Short-Acting Bronchodilators
        • 1.2.1.2 Corticosteroids
        • 1.2.1.3 Methylxanthines
        • 1.2.1.4 Long-Acting Bronchodilators
        • 1.2.1.5 Phosphodiesterase-4 Inhibitors
      • 1.2.2 by Application
        • 1.2.2.1 GOLD 1? FEV1 ? 80%
        • 1.2.2.2 GOLD 2? 50% ? FEV1 < 80%
        • 1.2.2.3 GOLD 3? 30% ? FEV1 < 50%
        • 1.2.2.4 GOLD 4? FEV1 < 30%
      • 1.2.3 by Regions

    2 Industry Chain

    • 2.1 Industry Chain Structure
    • 2.2 Upstream
    • 2.3 Market
      • 2.3.1 SWOT
      • 2.3.2 Dynamics

    3 Environmental Analysis

    • 3.1 Policy
    • 3.2 Economic
    • 3.3 Technology
    • 3.4 Market Entry

    4 Market Segmentation by Type

    • 4.1 Market Size
      • 4.1.1 Short-Acting Bronchodilators Market, 2013-2018
      • 4.1.2 Corticosteroids Market, 2013-2018
      • 4.1.3 Methylxanthines Market, 2013-2018
      • 4.1.4 Long-Acting Bronchodilators Market, 2013-2018
      • 4.1.5 Phosphodiesterase-4 Inhibitors Market, 2013-2018
    • 4.2 Market Forecast
      • 4.2.1 Short-Acting Bronchodilators Market Forecast, 2019-2024
      • 4.2.2 Corticosteroids Market Forecast, 2019-2024
      • 4.2.3 Methylxanthines Market Forecast, 2019-2024
      • 4.2.4 Long-Acting Bronchodilators Market Forecast, 2019-2024
      • 4.2.5 Phosphodiesterase-4 Inhibitors Market Forecast, 2019-2024

    5 Market Segmentation by Application

    • 5.1 Market Size
      • 5.1.1 GOLD 1? FEV1 ? 80% Market, 2013-2018
      • 5.1.2 GOLD 2? 50% ? FEV1 < 80% Market, 2013-2018
      • 5.1.3 GOLD 3? 30% ? FEV1 < 50% Market, 2013-2018
      • 5.1.4 GOLD 4? FEV1 < 30% Market, 2013-2018
    • 5.2 Market Forecast
      • 5.2.1 GOLD 1? FEV1 ? 80% Market Forecast, 2019-2024
      • 5.2.2 GOLD 2? 50% ? FEV1 < 80% Market Forecast, 2019-2024
      • 5.2.3 GOLD 3? 30% ? FEV1 < 50% Market Forecast, 2019-2024
      • 5.2.4 GOLD 4? FEV1 < 30% Market Forecast, 2019-2024

    6 Market Segmentation by Region

    • 6.1 Market Size
      • 6.1.1 Asia-Pacific
        • 6.1.1.1 Asia-Pacific Market, 2012-2018
        • 6.1.1.2 Asia-Pacific Market by Type
        • 6.1.1.3 Asia-Pacific Market by Application
      • 6.1.2 North America
        • 6.1.2.1 North America Market, 2012-2018
        • 6.1.2.2 North America Market by Type
        • 6.1.2.3 North America Market by Application
      • 6.1.3 Europe
        • 6.1.3.1 Europe Market, 2012-2018
        • 6.1.3.2 Europe Market by Type
        • 6.1.3.3 Europe Market by Application
      • 6.1.4 South America
        • 6.1.4.1 South America Market, 2012-2018
        • 6.1.4.2 South America Market by Type
        • 6.1.4.3 South America Market by Application
      • 6.1.5 Middle East & Africa
        • 6.1.5.1 Middle East & Africa Market, 2012-2018
        • 6.1.5.2 Middle East & Africa Market by Type
        • 6.1.5.3 Middle East & Africa Market by Application
    • 6.2 Market Forecast
      • 6.2.1 Asia-Pacific Market Forecast, 2019-2024
      • 6.2.2 North America Market Forecast, 2019-2024
      • 6.2.3 Europe Market Forecast, 2019-2024
      • 6.2.4 South America Market Forecast, 2019-2024
      • 6.2.5 Middle East & Africa Market Forecast, 2019-2024

    7 Market Competitive

    • 7.1 Market by Vendors
    • 7.2 Market Concentration
    • 7.3 Price & Factors
    • 7.4 Marketing Channel

    8 Major Vendors

    • 8.1 AstraZeneca
    • 8.2 Boehringer Ingelheim
    • 8.3 GSK
    • 8.4 Novartis
    • 8.5 Teva Pharmaceuticals
    • 8.6 Ache Laboratorios Farmaceuticos
    • 8.7 Almirall
    • 8.8 Aquinox Pharmaceuticals
    • 8.9 Ario Pharma
    • 8.10 Asmacure
    • 8.11 Astellas Pharma
    • 8.12 BioMarck Pharmaceuticals
    • 8.13 0

    9 Conclusion

    Summary
    The Drugs for Chronic Obstructive Pulmonary Disorder market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc.
    Based on products type, the report describes major products type share of regional market. Products mentioned as follows:
    Short-Acting Bronchodilators
    Corticosteroids
    Methylxanthines
    Long-Acting Bronchodilators
    Phosphodiesterase-4 Inhibitors
    Leading vendors in the market are included based on profile, business performance etc. Vendors mentioned as follows:
    AstraZeneca
    Boehringer Ingelheim
    GSK
    Novartis
    Teva Pharmaceuticals
    Ache Laboratorios Farmaceuticos
    Almirall
    Aquinox Pharmaceuticals
    Ario Pharma
    Asmacure
    Astellas Pharma
    BioMarck Pharmaceuticals
    0
    Based on Application, the report describes major application share of regional market. Application mentioned as follows:
    GOLD 1? FEV1 ? 80%
    GOLD 2? 50% ? FEV1 < 80%
    GOLD 3? 30% ? FEV1 < 50%
    GOLD 4? FEV1 < 30%
    Based on region, the report describes major regions market by products and application. Regions mentioned as follows:
    Asia-Pacific
    North America
    Europe
    South America
    Middle East & Africa

    Buy now